RE:ONCY Corporate Investor Presentation
Significant advantages with ONCY's pelareorep are that pelareorep is intravenously (IV) administered as opposed to intratumoral (IT) administration with other OV agents and that pelareorep is safe to use and can be manufactured at a cost efficient price point.
Furthermore, according to Wang et al. writing in the Journal for Immunotherapy for Cancer, " Mechanisms for intravenous delivery are being urgently sought to allow for simultaneous targeting of primary tumors and metastatic or disseminated cells which could produce a greater therapeutic effect."
As an IV delivered drug, ONCY's pelareorep meets this urgent need, and has thus resulted in a safe, effective and novel large molecule I/O biologic agent, which is eligible for 13 years of FDA market exclusivity once approved, under the IRA, in contrast to a small molecule cancer agents which only have 9 years of protection.
https://jitc.bmj.com/content/10/5/e004167